EyePoint Pharmaceuticals (STU:PV3B) Pretax Margin %

: -99.91% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. EyePoint Pharmaceuticals's Pre-Tax Income for the three months ended in Dec. 2023 was €-12.85 Mil. EyePoint Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €12.86 Mil. Therefore, EyePoint Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2023 was -99.91%.

The historical rank and industry rank for EyePoint Pharmaceuticals's Pretax Margin % or its related term are showing as below:

STU:PV3B' s Pretax Margin % Range Over the Past 10 Years
Min: -1795.71 Med: -246.08 Max: 24.25
Current: -153.66

STU:PV3B's Pretax Margin % is ranked better than
51.66% of 1026 companies
in the Biotechnology industry
Industry Median: -178.425 vs STU:PV3B: -153.66

EyePoint Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for EyePoint Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Pretax Margin %

Get a 7-Day Free Trial

-278.87

-131.82

-158.14

-246.97

-153.66

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pretax Margin %	Get a 7-Day Free Trial															-412.54	-275.46	-251.73	-82.96	-99.91

Competitive Comparison

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals Pretax Margin % Distribution

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Pretax Margin % falls into.

EyePoint Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

EyePoint Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-64.843	/	42.199
	=	-153.66 %

EyePoint Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-12.853	/	12.864
	=	-99.91 %

EyePoint Pharmaceuticals (STU:PV3B) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

EyePoint Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines